Sera Prognostics (NASDAQ:SERA) Director Sandra Aj Lawrence Sells 3,899 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) Director Sandra Aj Lawrence sold 3,899 shares of the company’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $3.05, for a total transaction of $11,891.95. Following the sale, the director directly owned 18,814 shares in the company, valued at $57,382.70. This represents a 17.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Sera Prognostics Trading Down 2.2%

NASDAQ:SERA opened at $3.10 on Wednesday. The stock has a market capitalization of $116.78 million, a P/E ratio of -3.65 and a beta of 1.00. Sera Prognostics, Inc. has a 1 year low of $1.37 and a 1 year high of $9.13. The firm has a 50 day moving average of $2.77 and a 200-day moving average of $2.88.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%.The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. As a group, analysts forecast that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SERA. Baker BROS. Advisors LP raised its stake in shares of Sera Prognostics by 1.2% during the first quarter. Baker BROS. Advisors LP now owns 5,498,170 shares of the company’s stock worth $20,233,000 after buying an additional 63,771 shares during the last quarter. Aberdeen Group plc grew its holdings in Sera Prognostics by 79.6% during the second quarter. Aberdeen Group plc now owns 2,227,367 shares of the company’s stock worth $6,170,000 after purchasing an additional 987,367 shares during the period. AWM Investment Company Inc. boosted its stake in shares of Sera Prognostics by 48.1% during the first quarter. AWM Investment Company Inc. now owns 866,837 shares of the company’s stock valued at $3,190,000 after purchasing an additional 281,703 shares in the last quarter. Captrust Financial Advisors increased its holdings in Sera Prognostics by 20.0% in the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after purchasing an additional 100,366 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Sera Prognostics by 11.8% during the fourth quarter. Northern Trust Corp now owns 272,860 shares of the company’s stock valued at $2,221,000 after purchasing an additional 28,863 shares during the period. Institutional investors own 54.64% of the company’s stock.

Analyst Ratings Changes

Separately, Wall Street Zen lowered Sera Prognostics from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.